{"classes":[{"categories":[{"measurements":[{"comment":"Not reached","groupId":"OG000","lowerLimit":"8.5","upperLimit":"NA","value":"21.1"},{"comment":"Not reached","groupId":"OG001","lowerLimit":"8.7","upperLimit":"NA","value":"9.2"},{"groupId":"OG002","lowerLimit":"6.4","upperLimit":"19.5","value":"14.7"},{"comment":"Not reached","groupId":"OG003","lowerLimit":"NA","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"7"}],"units":"Participants"}],"description":"Progression is defined using the Response Evaluation Criteria In Solid Tumors Criteria (RECIST) guideline v1.1 as a 20% increase in the sum of the longest diameter of target lesions, a measurable increase in a non-target lesion, or the appearance of new lesions at any location. Progression-free survival time is measured from the date of randomization to the date of first progression, death, or last known follow-up (censored). No statistical testing was done due to early study termination.","dispersionType":"95% Confidence Interval","groups":[{"description":"Induction erlotinib for 12 weeks followed by chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy. Patients who have had no response (partial or complete) after 6 weeks of induction therapy start chemoradiation therapy immediately.","id":"OG000","title":"EGFR: Erlotinib"},{"description":"Chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy.","id":"OG001","title":"EGFR: No Erlotinib"},{"description":"Induction crizotinib for 12 weeks followed by chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy. Patients who have had no response (partial or complete) after 6 weeks of induction therapy start chemoradiation therapy immediately.","id":"OG002","title":"ALK: Crizotinib"},{"description":"Chemotherapy (either cisplatin/etoposide or paclitaxel/carboplatin) and radiation therapy.","id":"OG003","title":"ALK: No Crizotinib"}],"paramType":"MEDIAN","populationDescription":"Eligible patients","reportingStatus":"POSTED","timeFrame":"From randomization to study termination. Maximum follow-up was 39.0 months","title":"Progression-free Survival","type":"PRIMARY","unitOfMeasure":"months"}